RVP Narrows Nine-Month Loss, Posts Q3 Profit Amid Sales Dip

TL;DR

**RVP's Q3 profit is a mirage; the nine-month loss and heavy reliance on China mean this stock is still a risky bet.**

AI Summary

Retractable Technologies Inc. (RVP) reported a net income of $371,047 for the three months ended September 30, 2025, a significant improvement from a net loss of $1,921,989 in the same period of 2024. However, for the nine months ended September 30, 2025, the company posted a net loss of $10,217,140, though this is an improvement from the $15,657,246 net loss in the prior year. Net sales for the three-month period decreased slightly to $10,085,723 from $10,346,857, but increased for the nine-month period to $28,826,629 from $23,975,584. Gross profit for the quarter was $1,685,904, a substantial turnaround from a gross loss of $14,810 in Q3 2024. The company recorded $1,900,000 in litigation proceeds for the nine months ended September 30, 2025, which positively impacted the net loss. Cash and cash equivalents decreased by $790,850 to $3,444,538 at September 30, 2025, from $4,235,388 at the beginning of the period. A key risk highlighted is the reliance on Chinese manufacturers, which accounted for 61.7% of products in the first nine months of 2025. The strategic outlook includes managing inventory write-downs, which amounted to approximately $1.2 million for the nine months ended September 30, 2025, primarily due to products nearing expiration.

Why It Matters

For investors, RVP's return to quarterly profitability, albeit modest at $371,047, signals a potential turning point after significant losses, though the nine-month loss of $10.2 million remains a concern. The substantial increase in gross profit from a loss to $1.68 million quarter-over-quarter indicates improved operational efficiency or pricing power. The company's heavy reliance on Chinese manufacturers (61.7% of products) introduces supply chain risk, which could impact product availability and costs for customers and ultimately RVP's competitive position in the medical device market. The $1.9 million litigation proceeds are a one-time boost, masking underlying operational challenges, and investors should scrutinize sustainable revenue growth and cost management.

Risk Assessment

Risk Level: high — The company reported a net loss of $10,217,140 for the nine months ended September 30, 2025, indicating ongoing financial challenges despite a profitable quarter. Furthermore, RVP's significant dependence on Chinese manufacturers for 61.7% of its products in the first nine months of 2025 exposes it to substantial supply chain and geopolitical risks.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence before considering RVP. While the Q3 net income is positive, the year-to-date net loss and high reliance on foreign manufacturing suggest significant underlying risks. Monitor future filings for sustained profitability and diversification of manufacturing sources.

Financial Highlights

debt To Equity

0.90

revenue

$28,826,629

operating Margin

-46.70%

total Assets

$146,434,200

total Debt

$70,277,087

net Income

$371,047

eps

N/A

gross Margin

5.47%

cash Position

$3,444,538

revenue Growth

+20.23%

Key Numbers

• $371,047 — Net income (for the three months ended September 30, 2025, compared to a net loss of $1,921,989 in Q3 2024)
• $(10,217,140) — Net loss (for the nine months ended September 30, 2025, an improvement from $(15,657,246) in the prior year)
• $10,085,723 — Net sales (for the three months ended September 30, 2025, a decrease from $10,346,857 in Q3 2024)
• $28,826,629 — Net sales (for the nine months ended September 30, 2025, an increase from $23,975,584 in the prior year)
• $1,685,904 — Gross profit (for the three months ended September 30, 2025, a significant improvement from a gross loss of $(14,810) in Q3 2024)
• $1,900,000 — Litigation proceeds (for the nine months ended September 30, 2025)
• $3,444,538 — Cash and cash equivalents (as of September 30, 2025, a decrease of $790,850 from the beginning of the period)
• 61.7% — Products from Chinese manufacturers (percentage of products obtained in the first nine months of 2025)
• $1.2 million — Inventory write-downs (for the nine months ended September 30, 2025)
• 29,937,159 — Common shares outstanding (as of November 3, 2025)

Key Players & Entities

• RETRACTABLE TECHNOLOGIES INC (company) — registrant
• Texas (location) — state of incorporation
• Little Elm, Texas (location) — manufacturing and administrative facilities
• China (location) — source of manufacturing
• NYSE American (regulator) — exchange where common stock is registered
• VanishPoint (product) — safety syringe product line
• EasyPoint (product) — blood collection product line
• SEC (regulator) — filing oversight
• Bloomberg (company) — publisher of analysis
• September 30, 2025 (date) — end of reporting period

FAQ

Risk Factors

• Reliance on Chinese Manufacturers [high — operational]: The company relies heavily on Chinese manufacturers for its products, with 61.7% of products sourced from this region in the first nine months of 2025. This concentration poses a significant operational risk due to potential supply chain disruptions, geopolitical factors, or changes in trade policies that could impact production and delivery.
• Inventory Write-Downs [medium — operational]: Retractable Technologies Inc. incurred approximately $1.2 million in inventory write-downs for the nine months ended September 30, 2025. This was primarily due to products nearing expiration, indicating potential issues with inventory management, demand forecasting, or product lifecycle management.

Industry Context

The medical device industry, particularly for safety-engineered sharps disposal, is characterized by stringent regulatory requirements and a focus on preventing needlestick injuries. Competition can arise from established players and new entrants offering innovative solutions. Trends include increasing adoption of safety devices driven by regulations and healthcare worker safety initiatives, as well as evolving waste management protocols.

Regulatory Implications

While not explicitly detailed in the provided text, the medical device sector is subject to regulations from bodies like the FDA in the US and similar agencies globally. Compliance with manufacturing standards, product safety, and labeling requirements is critical. Any product recalls or safety concerns could lead to significant financial penalties and reputational damage.

What Investors Should Do

1. Monitor inventory levels and write-down trends.
2. Assess the impact of litigation proceeds on profitability.
3. Evaluate the company's supply chain diversification strategy.
4. Analyze the trend in gross profit and operating expenses.

Glossary

TIA

This likely refers to 'Technology and Intellectual Property Agreement' or a similar contractual arrangement, as indicated by its significant impact on 'Other income' and 'Other long-term liabilities'. (The TIA contributes substantially to the company's other income and represents a large liability, impacting profitability and the balance sheet.)

Retained earnings

The cumulative net income of a company that has not been distributed to shareholders as dividends. (A significant decrease in retained earnings from $26,668,591 to $16,278,618 indicates substantial net losses over the period, partially offset by positive net income in the most recent quarter.)

Treasury stock

Stock that a company has repurchased from the open market. (The company holds treasury stock valued at $12,888,678, which reduces total stockholders' equity.)

Year-Over-Year Comparison

Retractable Technologies Inc. shows a mixed financial performance compared to the prior year. While net sales for the nine months ended September 30, 2025, increased by 20.23% to $28,826,629 from $23,975,584, the company still reported a net loss of $10,217,140, albeit improved from a $15,657,246 loss. A significant positive development is the turnaround in gross profit for the third quarter, moving from a loss of $14,810 to a profit of $1,685,904. However, total assets and cash reserves have decreased, and new risks related to inventory write-downs and continued reliance on Chinese manufacturing have emerged.

Filing Documents

• tmb-20250930x10q.htm (10-Q) — 1383KB
• tmb-20250930xex31d1.htm (EX-31.1) — 14KB
• tmb-20250930xex31d2.htm (EX-31.2) — 14KB
• tmb-20250930xex32.htm (EX-32) — 8KB
• 0001104659-25-112205.txt ( ) — 6645KB
• tmb-20250930.xsd (EX-101.SCH) — 35KB
• tmb-20250930_cal.xml (EX-101.CAL) — 48KB
• tmb-20250930_def.xml (EX-101.DEF) — 136KB
• tmb-20250930_lab.xml (EX-101.LAB) — 319KB
• tmb-20250930_pre.xml (EX-101.PRE) — 225KB
• tmb-20250930x10q_htm.xml (XML) — 1496KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 1 CONDENSED BALANCE SHEETS 1 CONDENSED STATEMENTS OF OPERATIONS 2 CONDENSED STATEMENTS OF CASH FLOWS 3 CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY 4 NOTES TO CONDENSED FINANCIAL STATEMENTS 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 21 Item 4.

Controls and Procedures

Controls and Procedures 22

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1A.

Risk Factors

Risk Factors 22 Item 5. Other Information 22 Item 6. Exhibits 23

SIGNATURES

SIGNATURES 24 Table of Contents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. RETRACTABLE TECHNOLOGIES, INC. CONDENSED BALANCE SHEETS (unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 3,444,538 $ 4,235,388 Accounts receivable, net 8,437,865 7,786,697 Investments in debt and equity securities, at fair value 30,503,005 40,328,308 Inventories 20,388,988 19,189,753 Income taxes receivable 662,359 978,851 Other current assets 691,470 753,062 Total current assets 64,128,225 73,272,059 Property, plant, and equipment, net 82,235,885 87,348,518 Other assets 70,090 103,625 Total assets $ 146,434,200 $ 160,724,202 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 4,574,836 $ 4,290,588 Current portion of long-term debt 359,102 332,480 Accrued compensation 885,030 1,073,357 Dividends payable 1,417,438 1,417,437 Accrued royalties to shareholder 827,275 789,358 Other accrued liabilities 1,558,643 873,254 Income taxes payable 5,322 4,442 Total current liabilities 9,627,646 8,780,916 Other long-term liabilities - TIA 59,402,231 63,872,553 Long-term debt, net of current maturities 623,605 900,042 Total liabilities 69,653,482 73,553,511 Stockholders' equity: Preferred stock, $ 1 par value: Class B; authorized: 5,000,000 shares Series II, Class B 156,200 156,200 Series III, Class B 74,245 74,245 Common Stock, no par value — — Additional paid-in capital 73,160,333 73,160,333 Retained earnings 16,278,618 26,668,591 Common stock in treasury – at cost ( 12,888,678 ) ( 12,888,678 ) Total stockholders' equity 76,780,718 87,170,691 Total liabilities and stockholders' equity $ 146,434,200 $ 160,724,202 See accompanying notes to condensed unaudited financial statements 1 Table of Contents RETRACTABLE TECHNOLOGIES, INC. CONDENSED STATEMENTS OF OPERATIONS (unaudited) Three Months Three

View Full Filing

View this 10-Q filing on SEC EDGAR